S&P 500   3,236.82 (-2.49%)
DOW   26,773.99 (-3.19%)
QQQ   262.36 (-1.69%)
AAPL   105.78 (-0.99%)
MSFT   198.11 (-1.14%)
FB   246.19 (-2.51%)
GOOGL   1,410.36 (-2.81%)
AMZN   2,903.00 (-1.76%)
NVDA   482.66 (-1.01%)
TSLA   432.99 (-2.07%)
BABA   267.76 (-1.71%)
CGC   15.64 (-4.40%)
MU   48.58 (-4.26%)
GE   6.36 (-7.56%)
AMD   75.59 (+0.88%)
T   28.55 (-1.31%)
F   6.88 (-4.84%)
ACB   6.28 (-3.83%)
GILD   63.65 (-2.15%)
NFLX   474.39 (+0.94%)
DIS   124.29 (-3.37%)
BAC   24.23 (-3.89%)
BA   156.25 (-3.03%)
S&P 500   3,236.82 (-2.49%)
DOW   26,773.99 (-3.19%)
QQQ   262.36 (-1.69%)
AAPL   105.78 (-0.99%)
MSFT   198.11 (-1.14%)
FB   246.19 (-2.51%)
GOOGL   1,410.36 (-2.81%)
AMZN   2,903.00 (-1.76%)
NVDA   482.66 (-1.01%)
TSLA   432.99 (-2.07%)
BABA   267.76 (-1.71%)
CGC   15.64 (-4.40%)
MU   48.58 (-4.26%)
GE   6.36 (-7.56%)
AMD   75.59 (+0.88%)
T   28.55 (-1.31%)
F   6.88 (-4.84%)
ACB   6.28 (-3.83%)
GILD   63.65 (-2.15%)
NFLX   474.39 (+0.94%)
DIS   124.29 (-3.37%)
BAC   24.23 (-3.89%)
BA   156.25 (-3.03%)
S&P 500   3,236.82 (-2.49%)
DOW   26,773.99 (-3.19%)
QQQ   262.36 (-1.69%)
AAPL   105.78 (-0.99%)
MSFT   198.11 (-1.14%)
FB   246.19 (-2.51%)
GOOGL   1,410.36 (-2.81%)
AMZN   2,903.00 (-1.76%)
NVDA   482.66 (-1.01%)
TSLA   432.99 (-2.07%)
BABA   267.76 (-1.71%)
CGC   15.64 (-4.40%)
MU   48.58 (-4.26%)
GE   6.36 (-7.56%)
AMD   75.59 (+0.88%)
T   28.55 (-1.31%)
F   6.88 (-4.84%)
ACB   6.28 (-3.83%)
GILD   63.65 (-2.15%)
NFLX   474.39 (+0.94%)
DIS   124.29 (-3.37%)
BAC   24.23 (-3.89%)
BA   156.25 (-3.03%)
S&P 500   3,236.82 (-2.49%)
DOW   26,773.99 (-3.19%)
QQQ   262.36 (-1.69%)
AAPL   105.78 (-0.99%)
MSFT   198.11 (-1.14%)
FB   246.19 (-2.51%)
GOOGL   1,410.36 (-2.81%)
AMZN   2,903.00 (-1.76%)
NVDA   482.66 (-1.01%)
TSLA   432.99 (-2.07%)
BABA   267.76 (-1.71%)
CGC   15.64 (-4.40%)
MU   48.58 (-4.26%)
GE   6.36 (-7.56%)
AMD   75.59 (+0.88%)
T   28.55 (-1.31%)
F   6.88 (-4.84%)
ACB   6.28 (-3.83%)
GILD   63.65 (-2.15%)
NFLX   474.39 (+0.94%)
DIS   124.29 (-3.37%)
BAC   24.23 (-3.89%)
BA   156.25 (-3.03%)
Log in
OTCMKTS:GTBP

GT Biopharma Stock Forecast, Price & News

$0.17
0.00 (-0.30 %)
(As of 09/18/2020 08:10 PM ET)
Add
Compare
Today's Range
$0.17
Now: $0.17
$0.17
50-Day Range
$0.16
MA: $0.18
$0.20
52-Week Range
$0.07
Now: $0.17
$0.27
Volume92,001 shs
Average Volume139,584 shs
Market Capitalization$12.36 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.38
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate targeting CD33+ malignancies; OXS-C3550, a next-generation version of OXS-3550 containing a modified CD16 component; and OXS-1615, a single-chain fusion protein that targets epithelial tumors and CD133 positive solid tumors. It also develops central nervous system central nervous system, such as GTP-004, a fixed-dose combination tablet that has completed Phase I clinical trial for the treatment of the muscle weakness associated with myasthenia gravis; PainBrake, a patented formulation of carbamazepine to treat neuropathic pain; and GTP-011, a transdermal product for the prevention of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was founded in 1965 and is based in Westlake Village, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GTBP
Previous SymbolOTCMKTS:OXISD
CUSIPN/A
CIKN/A
Phone800-304-9888

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.29) per share

Profitability

Net Income$-38,650,000.00

Miscellaneous

Employees3
Market Cap$12.36 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$0.17
0.00 (-0.30 %)
(As of 09/18/2020 08:10 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GTBP News and Ratings via Email

Sign-up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GT Biopharma (OTCMKTS:GTBP) Frequently Asked Questions

How has GT Biopharma's stock been impacted by COVID-19?

GT Biopharma's stock was trading at $0.1880 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GTBP stock has decreased by 12.2% and is now trading at $0.1650.
View which stocks have been most impacted by COVID-19
.

When is GT Biopharma's next earnings date?

GT Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for GT Biopharma
.

Are investors shorting GT Biopharma?

GT Biopharma saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 13,000 shares, an increase of 20.4% from the August 15th total of 10,800 shares. Based on an average trading volume of 221,100 shares, the short-interest ratio is presently 0.1 days.
View GT Biopharma's Short Interest
.

Who are some of GT Biopharma's key competitors?

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GT Biopharma investors own include Cronos Group (CRON), Canopy Growth (CGC), Canopy Growth (WEED), Auxly Cannabis Group (CBWTF), KushCo (KSHB), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Cara Therapeutics (CARA), PotNetwork (POTN) and American Cannabis (AMMJ).

Who are GT Biopharma's key executives?

GT Biopharma's management team includes the following people:
  • Mr. Anthony J. Cataldo, Chairman of Directors, CEO & Pres (Age 67)
  • Mr. Steven W. Weldon, CFO, Principal Accounting Officer & Director (Age 43)

What is GT Biopharma's stock symbol?

GT Biopharma trades on the OTCMKTS under the ticker symbol "GTBP."

How do I buy shares of GT Biopharma?

Shares of GTBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GT Biopharma's stock price today?

One share of GTBP stock can currently be purchased for approximately $0.17.

How big of a company is GT Biopharma?

GT Biopharma has a market capitalization of $12.36 million. GT Biopharma employs 3 workers across the globe.

What is GT Biopharma's official website?

The official website for GT Biopharma is www.gtbiopharma.com.

How can I contact GT Biopharma?

GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The company can be reached via phone at 800-304-9888 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.